Skip to main content
Premium Trial:

Request an Annual Quote

EU Therapeutics Program Hires Biobase to Help Develop Target ID Methods

NEW YORK (GenomeWeb News) — A group of European research institutes has hired Biobase to help it develop informatics tools and experimental methods for identifying therapeutic targets, the company said today.
Biobase said it will help develop bioinformatics and cheminformatics for the European Union-commissioned Net2Drug project, which is a consortium of institutes from Europe and Russia that represents interdisciplinary fields including toxicology, systems biology, pharmacology, and cancer.
The project “will integrate different omics datasets such as proteomics and genomics into cohesive networks” to help study diseases.
Any resulting methods or technologies will be tested on “certain tumor types,” particularly on breast cancer, said Alexander Kel, Biobase senior vice president of R&D.
Net2Drug is part of the EU’s Sixth Framework program, which was funded with $2.5 billion between 2002 and 2006, and which sets aside as much as $475 million for cancer research.
Financial terms of the agreement were not released.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.